[Progress of the ATLL study: an overview].
Yamada
Yasuaki
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D017209:Apoptosis / Q000235:genetics; D016190:Carboplatin / Q000008:administration & dosage; D019941:Cyclin-Dependent Kinase Inhibitor p16; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D019942:Genes, p16; D016158:Genes, p53 / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D015368:Human T-lymphotropic virus 1 / Q000235:genetics / Q000472:pathogenicity; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000209:etiology / Q000628:therapy / Q000635:transmission; D017254:Leukemic Infiltration; D009154:Mutation; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D018121:Receptors, Cytokine; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
D019941:Cyclin-Dependent Kinase Inhibitor p16; D009607:Nitrosourea Compounds; D018121:Receptors, Cytokine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D016190:Carboplatin; D014751:Vindesine